Greene Barry E
SEC-identified person · CIK 1291963 Identifier-verified
Public-company roles (from insider filings)
| Company | Capacity as filed | Filings |
|---|---|---|
| Dyne Therapeutics, Inc. DYN | Director | filed 2026–2026 |
| Karyopharm Therapeutics Inc. KPTI | Director | filed 2013–2026 |
| Sage Therapeutics, Inc. SAGE | Director · President and CEO | filed 2020–2025 |
| Acorda Therapeutics, Inc. ACOR | Director | filed 2007–2021 |
| Bcls Acquisition Corp. BLSA | Director | filed 2020–2020 |
| Alnylam Pharmaceuticals, INC. ALNY | President and COO | filed 2006–2020 |
| Regulus Therapeutics Inc. RGLS | Director | filed 2012–2012 |
All roles under one Commission-assigned identifier - the same person by the SEC's own record, not by name matching. From the SEC's insider-transaction filings (Forms 3, 4 and 5). Every reporting director and officer carries a Commission-assigned identifier (CIK), so these footprints are identifier-verified - no name matching involved. Insiders file when they transact, so dates are filing dates: "last filed" never means "served until". This layer is not yet joined to the nonprofit register - identity joins ship only after independent review.